ArticleJournal of medical biochemistry2025
Comparison of the effects of zoledronic acid versus denosumab on bone metabolism, inflammatory response, and immunoglobulins in breast cancer patients with bone metastases.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to compare the effects of Zoledronic Acid (ZA) versus Denosumab (DEN) on bone metabolism, inflammatory response, and immunoglobulins in breast cancer (BC) patients with bone metastases. Methods: The potential study population consisted of 163 patients with bone metastases BC admitted from May 2023 to June 2024. Through propensity score matching (PSM), 122 patients were included, with 61 patients in the ZA group (treated with ZA) and 61 patients in the DEN group (treated with DEN). Levels of tartrate-resistant acid phosphatase 5b (TRACP-5b), bone glutamyl protein (BGP), bone alkaline phosphatase (BALP), and 25-hydroxyvitamin D3 (25(OH)D3) were measured before and after treatment. Additionally, bone mineral density (BMD) of the lumbar spine (L1-L4) and hip, as well as levels of inflammatory factors and immunoglobulins, were assessed. Results: After PSM, baseline characteristics were balanced between the ZA and DEN groups (P > 0.05). No significant difference was observed in post-treatment BMD between the two groups (P > 0.05). However, the DEN group showed significantly lower TRACP-5b and BGP levels and notably higher BALP and 25(OH)D3 levels compared to the ZA group (P <0.05). In contrast, the ZA group exhibited lower levels of inflammatory factors and higher immunoglobulin levels than the DEN group (P < 0.05). Regarding safety, a lower incidence of adverse reactions was determined in the DEN group versus the ZA group (P < 0.05). Conclusions: In the treatment of BC with bone metastases, DEN demonstrated superior benefits for bone metabolism, while ZA showed better regulation of inflammatory response and immune function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.